After achieving HIV-@ RNA < @ copies/mL on two consecutive occasions between weeks @ and @ after baseline , @ patients ( baseline : median HIV-@ RNA @ log@ copies/mL ; median CD@ count @ cells/L ) were randomized to receive abacavir/lamivudine/zidovudine ( ABC/@TC/ZDV ) ( n = @ ) or to continue the PI-based ART ( n = @ ) .